核糖核苷酸还原酶M2在小脑髓母细胞瘤中的功能及机制

doi:10.3969/j.issn.1004-616x.2023.04.006

癌变·畸变·突变 ›› 2023, Vol. 35 ›› Issue (4): 279-284,291.doi: 10.3969/j.issn.1004-616x.2023.04.006

核糖核苷酸还原酶M2在小脑髓母细胞瘤中的功能及机制

张琪^1,2, 吴菁¹, 张晨璐¹

1. 复旦大学附属中山医院肿瘤内科, 上海 200032;
2. 复旦大学附属金山医院肿瘤内科, 上海 201508

收稿日期:2023-04-07 修回日期:2023-05-04 出版日期:2023-07-30 发布日期:2023-08-04
通讯作者: 张晨璐
作者简介:张琪，E-mail：vivid990@126.com。
基金资助:
上海市青年科技英才扬帆计划(19YF14071000)

The biological function and mechanism of ribonucleotide reductase subunit M2 in medulloblastoma

ZHANG Qi^1,2, WU Jing¹, ZHANG Chenlu¹

1. Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032;
2. Department of Medical Oncology, Jinshan Hospital, Fudan University, Shanghai 201508, China

Received:2023-04-07 Revised:2023-05-04 Online:2023-07-30 Published:2023-08-04

摘要/Abstract

摘要： 目的：探讨核糖核苷酸还原酶M2(RRM2)在小脑髓母细胞瘤中的功能和机制。方法：分析GEO数据库中髓母细胞瘤患者的生存和RRM2表达水平的关系。通过免疫组化并结合数据库分析RRM2在小脑髓母细胞瘤和正常小脑组织中的表达。分别通过CCK-8细胞增殖实验、Transwell实验、流式细胞术检测RRM2对小脑髓母细胞瘤细胞系Daoy和D283的增殖、迁移、细胞周期和凋亡的调控作用。通过转录组测序(RNA-seq)探索下游分子机制。采用配对t检验和独立样本t检验进行统计学分析。结果：通过GEO数据库分析发现高表达RRM2的髓母细胞瘤患者相较于低表达组的总生存期更短、预后更差(P<0.05)。免疫组化及数据库分析结果显示RRM2在小脑髓母细胞瘤中的表达明显高于正常小脑组织(P<0.05)。与对照组比较，CCK-8细胞增殖实验、Transwell实验提示过表达RRM2促进肿瘤细胞增殖和迁移(P<0.05)，敲低RRM2减少肿瘤细胞增殖和迁移(P<0.05)；过表达RRM2能够明显增加S期的细胞比例(P<0.05)，且明显减少细胞凋亡(P<0.05)。RNA-seq结果显示敲低RRM2后有3 454个基因表达上调，3 332个基因表达下调。KEGG分析显示RRM2敲低后多个信号通路受到影响，包括FOXO、细胞周期、核糖体生物合成等。结论：RRM2在小脑髓母细胞瘤中高表达且与预后不良有关，其具有促进小脑髓母细胞瘤细胞增殖、迁移，减少细胞凋亡的能力。

关键词: 小脑髓母细胞瘤, 核糖核苷酸还原酶M2, 增殖, 迁移, 细胞凋亡

Abstract: OBJECTIVE： To investigate biological functions and mechanism of ribonucleotide reductase subunit M2 (RRM2) in medulloblastoma. METHODS： Relationships between survival and the levels of RRM2 expression in GEO database (GSE85217) were analyzed. Expressions of RRM2 in medulloblastoma and normal cerebellar tissues were analyzed using immunohistochemistry and database. CCK-8 proliferation experiments，transwell experiments，and flow cytometry were used to study the effects of RRM2 on proliferation，migration，cell cycle，and apoptosis of medulloblastoma cell lines Daoy and D283. RNA sequencing (RNA-seq) was used to explore downstream molecular mechanisms. Paired t-test and independent sample t-test were used for statistical analysis. RESULTS： Through the analysis of GEO database，survival of medulloblastoma patients was worse in the RRM2-high group than that in low group (P<0.05). The results of immunohistochemistry and database showed that expressions of RRM2 were significantly higher in medulloblastoma than that in normal cerebellar tissues (P<0.05). Compared to the control groups，overexpressions of RRM2 promoted tumor cell proliferation and migration，while knockdown of RRM2 reduced tumor cell proliferation and migration. In addition，overexpressions of RRM2 significantly increased the proportions of cells in the S phase (P<0.05) and reduced apoptosis (P<0.05). After knockdown of RRM2，RNA-seq results showed that 3 454 genes were up-regulated and 3 332 genes were down-regulated. KEGG analysis showed that multiple signal pathways were affected，including FOXO，cell cycle，ribosome biosynthesis，etc. CONCLUSION： RRM2 was highly expressed in medulloblastoma and the expression was negatively related to prognosis. In addition，RRM2 expression promoted proliferation and migration of medulloblastoma cells and reduced apoptosis.

Key words: edulloblastoma, RRM2, proliferation, migration, apoptosis

中图分类号:

R730.2

张琪, 吴菁, 张晨璐. 核糖核苷酸还原酶M2在小脑髓母细胞瘤中的功能及机制[J]. 癌变·畸变·突变, 2023, 35(4): 279-284,291.

ZHANG Qi, WU Jing, ZHANG Chenlu. The biological function and mechanism of ribonucleotide reductase subunit M2 in medulloblastoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 279-284,291.

参考文献

[1] NORTHCOTT P A, ROBINSON G W, KRATZ C P, et al. Medulloblastoma[J]. Nat Rev Dis Primers, 2019, 5(1): 11.
[2] WANG J, GARANCHER A, RAMASWAMY V, et al. Medulloblastoma: from molecular subgroups to molecular targeted therapies[J]. Annu Rev Neurosci, 2018, 41: 207-232.
[3] NORDLUND P, REICHARD P. Ribonucleotide reductases[J]. Annu Rev Biochem, 2006, 75: 681-706.
[4] KRETSCHMER C, STERNER-KOCK A, SIEDENTOPF F, et al. Identification of early molecular markers for breast cancer[J]. Mol Cancer, 2011, 10(1): 15.
[5] GRADE M, HUMMON A B, CAMPS J, et al. A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets[J]. Int J Cancer, 2011, 128(5): 1069-1079.
[6] XU X, PAGE J L, SURTEES J A, et al. Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms[J]. Cancer Res, 2008, 68(8): 2652-2660.
[7] TAYLOR M D, NORTHCOTT P A, KORSHUNOV A, et al. Molecular subgroups of medulloblastoma: the current consensus[J]. Acta Neuropathol, 2012, 123(4): 465-472.
[8] HOVESTADT V, AYRAULT O, SWARTLING F J, et al. Medulloblastomics revisited: biological and clinical insights from thousands of patients[J]. Nat Rev Cancer, 2020, 20(1): 42-56.
[9] MAZZU Y Z, ARMENIA J, CHAKRABORTY G, et al. A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2(RRM2)[J]. Clin Cancer Res, 2019, 25(14): 4480-4492.
[10] AYE Y, LI M, LONG M J C, et al. Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies[J]. Oncogene, 2015, 34(16): 2011-2021.
[11] PFISTER S X, MARKKANEN E, JIANG Y Y, et al. Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation[J]. Cancer Cell, 2015, 28(5): 557-568.
[12] ZHAN Y Q, JIANG L S, JIN X H, et al. Inhibiting RRM2 to enhance the anticancer activity of chemotherapy[J]. Biomedecine Pharmacother, 2021, 133: 110996.
[13] LI C, ZHENG J F, CHEN S, et al. RRM2 promotes the progression of human glioblastoma[J]. J Cell Physiol, 2018, 233(10): 6759-6767.
[14] HAN P, LIN Z R, XU L H, et al. Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma[J]. Mol Med Rep, 2015, 12(1): 401-409.
[15] LIU X, PENG J M, ZHOU Y Y, et al. Silencing RRM2 inhibits multiple myeloma bytargeting the Wnt/β-catenin signaling pathway[J]. Mol Med Rep, 2019, 20(3): 2159-2166.
[16] XIONG W, ZHANG B, YU H X, et al. RRM2 regulates sensitivity to sunitinib and PD-1 blockade in renal cancer by stabilizing ANXA1 and activating the AKT pathway[J]. Adv Sci, 2021, 8(18): e2100881.
[17] LIU Y, AO X, DING W, et al. Critical role of FOXO3a in carcinogenesis[J]. Mol Cancer, 2018, 17(1): 104.
[18] DAS T P, SUMAN S, ALATASSI H, et al. Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer[J]. Cell Death Dis, 2016, 7(2): e2111.

核糖核苷酸还原酶M2在小脑髓母细胞瘤中的功能及机制

The biological function and mechanism of ribonucleotide reductase subunit M2 in medulloblastoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	史建红, 陈丁雄, 卢晓童, 郝佳洁, 蔡岩, 王明荣, 张钰. ICG-001对食管鳞癌细胞增殖的抑制作用及其分子机制[J]. 癌变·畸变·突变, 2023, 35(3): 187-191,196.
[2]	冯丹, 范志露, 王意浓, 李赛, 郭婧, 蔡岩, 张钰, 魏文强, 王明荣, 郝佳洁. P4HA2通过激活EGFR/AKT/S6信号通路促进食管鳞癌细胞的增殖[J]. 癌变·畸变·突变, 2023, 35(2): 87-94,101.
[3]	陈双, 彭中芮, 吴桢雯, 郭东北, 孙美君, 李蕾. 明日叶查尔酮对小鼠急性酒精性肝损伤的保护作用[J]. 癌变·畸变·突变, 2023, 35(2): 95-101.
[4]	张军军, 梁乐平. PTEN C末端对鼻咽癌细胞迁移及增殖能力的影响[J]. 癌变·畸变·突变, 2022, 34(6): 434-438.
[5]	毕佳欣, 王晓雪, 赵若晗, 韩旭, 宋洁. 着丝粒蛋白T在乳腺癌中表达及其启动子区变异的研究[J]. 癌变·畸变·突变, 2022, 34(5): 327-334.
[6]	齐建考, 汤肖, 孙世辉, 寇艳方, 崔志勤. 复方皂刺汤对顺铂联合吉西他滨抑制非小细胞肺癌生长的作用及其机制研究[J]. 癌变·畸变·突变, 2022, 34(5): 366-372,403.
[7]	梁峰, 张玮, 王胜杰, 武雪亮, 岳磊, 张迎春. 长链非编码RNARUNX1-IT1通过靶向miR-21对结直肠癌细胞迁移和侵袭的影响[J]. 癌变·畸变·突变, 2022, 34(5): 378-383,387.
[8]	涂永梅, 于卫华, 彭洁, 刘江正, 刘瑞, 吴昊, 孔德钦, 何改花, 李文丽, 王冲. 鸢尾素介导抗炎和抗氧化作用的机制[J]. 癌变·畸变·突变, 2022, 34(4): 247-254,261.
[9]	张月, 王耀一, 武雪亮, 张志生, 杨修明, 姜洋, 乔志飞, 梁晚平, 薛军. ¹²⁵I粒子联合AZD1152对三阴性乳腺癌细胞增殖和凋亡的影响[J]. 癌变·畸变·突变, 2022, 34(4): 295-299,306.
[10]	陈丁雄, 朱依青, 史建红, 蔡岩, 郝佳洁, 王明荣, 梁建伟, 张钰. DNAJB6b通过激活AKT通路增强结直肠癌细胞的侵袭迁移能力[J]. 癌变·畸变·突变, 2022, 34(3): 178-183.
[11]	张琪, 刘宇峻, 庄喜兵, 乔田奎. 附子提取物对肺癌A549细胞增殖抑制及放射增敏作用的研究[J]. 癌变·畸变·突变, 2022, 34(3): 227-232.
[12]	丁赛, 张红霞, 朱海英. 脐带来源的华通氏胶间充质干细胞的分离、特性及应用前景[J]. 癌变·畸变·突变, 2022, 34(3): 233-236.
[13]	王蕊, 刘颖, 吴娟, 纪晓坤, 马阳, 郭晓, 杜芸. 胸腔积液肺腺癌细胞中CXCR4、Ki67、MDM2、N-cadherin的表达及其与EGFR突变状态的关系[J]. 癌变·畸变·突变, 2022, 34(2): 114-118.
[14]	李柏茹, 秦双建, 蔡颖, 李闰冰, 关岚, 肖芳, 曾明, 徐新云. PM_2.5混悬液对3种癌细胞侵袭和迁移能力的影响[J]. 癌变·畸变·突变, 2022, 34(2): 124-128,133.
[15]	赵岩, 孙震晓. 二甲双胍抑制人MDA-MB-231细胞增殖及迁移的体外实验研究[J]. 癌变·畸变·突变, 2022, 34(1): 35-39.